Trade Mark Journal No.2018/016 20 April 2018

WO0000001393298 (1,5)

Office of origin: United States

Date of International Registration:21 December 2017
Date of designation in the UK: 21 December 2017
Image for mark WO0000001393298 AFIBROMER

International priority date claimed: 28 June 2017 (United States) (87508729)
Class 1
Chemical agents for coating of medical devices, medical materials, and for encapsulating pharmaceutical agents and cells; reagents for research purposes; reagents for scientific or medical research use.
Class 5
Chemical, pharmaceutical, biopharmaceutical and biomedical agents for medical use, namely, immune response modulating agents; chemical agents for pharmaceutical or medical purposes, namely, immune response modulating agents; pharmaceutical agents for encapsulating transplanted cells to prevent the risk of rejection from immune attack, for medical purposes; pharmaceutical preparations for the prevention and treatment of fibrosis, inflammation, cancer or infection; drug delivery agents in the form of coatings for capsules that facilitate the tolerance and delivery of pharmaceutical preparations.

Sigilon Therapeutics, Inc.

Representative: Christina M. Licursi, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA